Combination therapy with XXXX and cetuximab effectively suppresses growth of @entity14 cells regardless of @entity984 status.

@entity1 @entity5921 @entity137 @entity5 @entity984 @entity98 @entity14 @entity4381 @entity694
UNASSIGNED: Targeted molecular therapy is an effective anticancer strategy. Anti-EGFR monoclonal antibodies such as cetuximab (CTX) have been approved for the treatment of various @entity5 , including @entity14 ( @entity14 ) with wild-type @entity984 . However, their efficacy in @entity1 with @entity984 mutations has not been established. Therefore, we investigated whether CTX treatment was effective as a single agent or in combination with @entity4381 ( @entity5921 ) in @entity1 @entity14 cell lines with different @entity984 status. @entity14 cell lines SW48 (wild-type @entity984 ) and LS174T (mutant @entity984 ) were treated with @entity5921 , CTX and a combination of both drugs. @entity137 was measured using the @entity98 assay. Changes in the levels of intracellular signaling proteins were evaluated using western blot analysis. Finally, we evaluated the efficacy of the combination treatment in an in vivo xenograft model. We observed that @entity5921 apparently inhibited growth in both cell lines, whereas CTX showed little effect. @entity5921 also increased the levels of unprenylated RAS. Combined @entity5921 and CTX treatment was synergistic in both cell lines and was associated with inhibition of the RAS-MAPK and AKT-mTOR signaling pathways. Furthermore, the combination treatment was more effective in suppressing the growth of xenografts derived from both SW48 and LS174T cells; this effect was associated with increased apoptosis. These results demonstrate that @entity5921 inhibits the growth of @entity694 cells regardless of @entity984 status, and combination therapy using @entity5921 and CTX enhances this growth suppression. These findings suggest a novel strategy for the treatment of @entity14 independent of @entity984 mutational status.
